Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?

MLA

Elif Hindié, et al. Do Clinical, Histological or Immunohistochemical Primary Tumour Characteristics Translate into Different 18F-FDG PET/CT Volumetric and Heterogeneity Features in Stage II/III Breast Cancer? July 2015. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b190a9dd447ae35aff0cc49a5bd45683&authtype=sso&custid=ns315887.

APA

Elif Hindié, Antoine Martineau, Pascal Merlet, Catherine Cheze Le Rest, David Groheux, Mathieu Hatt, Mohamed Majdoub, Anne de Roquancourt, Marc Espié, Dimitris Visvikis, & Florent Tixier. (2015). Do clinical, histological or immunohistochemical primary tumour characteristics translate into different 18F-FDG PET/CT volumetric and heterogeneity features in stage II/III breast cancer?

Chicago

Elif Hindié, Antoine Martineau, Pascal Merlet, Catherine Cheze Le Rest, David Groheux, Mathieu Hatt, Mohamed Majdoub, et al. 2015. “Do Clinical, Histological or Immunohistochemical Primary Tumour Characteristics Translate into Different 18F-FDG PET/CT Volumetric and Heterogeneity Features in Stage II/III Breast Cancer?,” July. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b190a9dd447ae35aff0cc49a5bd45683&authtype=sso&custid=ns315887.